Targeting HER2-positive Metastatic Breast Cancer
The FDA has expanded the use of the molecularly targeted therapeutic neratinib to include the treatment of certain patients...
Progress Against Cancer
The FDA has expanded the use of the molecularly targeted therapeutic neratinib to include the treatment of certain patients...
“There’s a clear connection between cancer and the gut microbiome,” began Matthew Redinbo, PhD, at the opening keynote address...
Tracking health problems in young cancer survivors and other cancer news of the week from Cancer Today magazine staff.
Circulating tumor DNA (ctDNA) was first detected over 30 years ago, but its potential uses for cancer diagnosis and...
February is National Cancer Prevention Month. We recently had the opportunity to speak with American Association for Cancer Research...
A study illuminates the alcohol consumption habits of cancer survivors.
Today is International Day of Women and Girls in Science, a United Nations initiative aimed at encouraging full and...
Due to the high cost of care and cost-sharing, many of the more than 16.9 million survivors in the...
Medical oncologist and lung cancer expert Roy S. Herbst, MD, PhD, discusses early data on drugs that target a...
A roundup of the week in cancer research news from the staff of Cancer Today magazine.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 44,000 members worldwide drive progress against cancer.
Donate Today